“Chronic Periodontitis in a Patient with Multiple Sclerosis_ Case Report”Rayeheh Tavajohi1, Amitis Sarbaz2, Hooshyar Honarmand1, Abdorreza Naser Moghadasi3*1Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran2Georgia School of Orthodontics, Atlanta, Georgia, USA3Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, IranCorrespondence: Abdorreza Naser Moghadasi; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Email: [email protected]

The recombinant C-type lectin protein (r-CTL) derived from Toxocara canis larvae is thought to play a role in promoting regulatory T cells-dominant immune responses in toxocariasis. This study aimed to highlight the therapeutic potential of the r-CTL protein in ameliorate the disability scores of EAE by enhancing the regulatory T cells population. The recombinant C-type lectin was expressed in prokaryotic systems and purified through Ni-NTA spin columns. Balb/C57 mice were divided into six groups, with EAE induced in all groups except the healthy control group. Group I (n=10) received r-CTL treatment post EAE induction, Group II (n=10) underwent EAE induction only, Group III (n=5) received treatment with E. coli lysate proteins containing E. coli BL21 and plasmid pET32a without r-CTL after EAE induction, Group IV (n=5) received sterile PBS after EAE induction, Group V (n=5) served as the healthy control group, and Group VI (n=5) received only r-CTL treatment. The study’s findings revealed that r-CTL treatment significantly decreased disability scores in EAE-induced mice. There was a notable increase in the population of CD4+, CD25+, FOXP3+ regulatory T cells following r-CTL treatment. The gene expression levels of IL-10, FOXP3, and GATA3 were significantly elevated in the r-CTL treated group, while the expression of T-bet and RORγ genes was reduced. Treatment with r-CTL significantly mitigated cell infiltration and demyelination in both the spinal cord and brain. In conclusion, these findings suggest that the r-CTL protein may have promising applications in the treatment of MS and warrant further investigation into its therapeutic mechanisms.